Topic Hub
106 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.
Explore
Showing 106 of 106 clinical reviews.
Compare the side-effect profiles of liraglutide and retatrutide, including GI tolerability, cardiovascular signals, and dose-dependent adverse events from SCALE and Phase 2 trial data.
Read clinical reviewA clinical comparison of liraglutide and retatrutide covering weight-loss efficacy, pricing, insurance coverage, and practical access for patients considering GLP-1 therapy.
Read clinical reviewA clinical comparison of liraglutide and retatrutide for weight loss, examining trial data from SCALE Obesity and Phase 2 results, dosing, mechanisms, and real-world considerations.
Read clinical reviewCompare liraglutide and retatrutide for weight loss, including efficacy data from SCALE and Phase 2 trials, and clinical guidance for switching between these GLP-1 receptor agonists.
Read clinical reviewA head-to-head comparison of liraglutide and dulaglutide (Trulicity) covering cost, insurance access, dosing convenience, weight loss, cardiovascular outcomes, and switching protocols.
Read clinical reviewA clinical comparison of liraglutide and dulaglutide (Trulicity) covering weight loss, A1C reduction, cardiovascular outcomes, dosing, and cost. Evidence from SCALE, AWARD, and REWIND trials.
Read clinical reviewA clinical comparison of liraglutide and dulaglutide (Trulicity) side effects, tolerability, GI symptoms, injection-site reactions, and safety data from SCALE and REWIND trials.
Read clinical reviewA clinical guide to switching between liraglutide and dulaglutide (Trulicity), including dose equivalence, washout timing, side-effect management, and what the trial data actually shows for each GLP-1 receptor agonist.
Read clinical reviewA clinical comparison of Mounjaro (tirzepatide) and liraglutide covering efficacy, pricing, insurance coverage, and access pathways for weight loss and type 2 diabetes.
Read clinical reviewA clinical comparison of Mounjaro (tirzepatide) and liraglutide side effects, covering GI tolerability, pancreatitis risk, thyroid signals, and real-world discontinuation rates from SURPASS and SCALE trials.
Read clinical reviewA clinical comparison of Mounjaro (tirzepatide) and retatrutide covering cost, insurance access, trial efficacy data, and practical switching guidance for patients and prescribers.
Read clinical reviewA cross-trial comparison of tirzepatide (Mounjaro) and retatrutide for weight loss and glycemic control, with data from SURPASS and Phase 2 trials.
Read clinical reviewA cross-trial comparison of tirzepatide (Mounjaro) and retatrutide adverse events, covering GI tolerability, cardiovascular signals, hepatic effects, and dose-escalation strategies.
Read clinical reviewClinical comparison of Mounjaro (tirzepatide) and retatrutide for weight loss and metabolic health, including guidance on switching protocols, trial data, and what to expect during transition.
Read clinical reviewCompare the side-effect profiles of Mounjaro (tirzepatide) and Rybelsus (oral semaglutide) using clinical trial data from SURPASS-2 and PIONEER programs.
Read clinical reviewCompare tirzepatide (Mounjaro) and oral semaglutide (Rybelsus) for A1C reduction, weight loss, and clinical outcomes using SURPASS and PIONEER trial data.
Read clinical reviewA clinical comparison of Mounjaro (tirzepatide) and Rybelsus (oral semaglutide), including efficacy data, mechanism differences, and practical guidance for switching between the two GLP-1 medications.
Read clinical reviewA head-to-head comparison of Mounjaro (tirzepatide) and Saxenda (liraglutide 3 mg) covering weight-loss efficacy, pricing, insurance coverage, and access for 2026.
Read clinical reviewA clinical comparison of Mounjaro (tirzepatide) and Saxenda (liraglutide 3 mg) covering weight loss efficacy, A1C reduction, trial data, side effects, and switching guidance.
Read clinical reviewA clinical comparison of Mounjaro (tirzepatide) and Saxenda (liraglutide 3 mg) covering weight loss efficacy, mechanism differences, and how to switch safely between them.
Read clinical reviewA detailed side-effect comparison of Mounjaro (tirzepatide) and Trulicity (dulaglutide), including GI tolerability, hypoglycemia risk, cardiovascular safety, and discontinuation rates from SURPASS and REWIND trial data.
Read clinical reviewA clinical comparison of Mounjaro (tirzepatide) and Trulicity (dulaglutide) covering A1C reduction, weight loss, cardiovascular outcomes, and dosing across major trials.
Read clinical reviewA clinical comparison of Mounjaro (tirzepatide) and Trulicity (dulaglutide), including efficacy data from SURPASS and REWIND trials, and a step-by-step guide for switching between these GLP-1 medications.
Read clinical reviewA head-to-head comparison of Ozempic (semaglutide) and liraglutide covering cost, insurance access, clinical efficacy, and switching protocols for weight loss and type 2 diabetes.
Read clinical reviewA clinical comparison of Ozempic (semaglutide) and liraglutide for glycemic control and weight loss, with trial data from SUSTAIN-7, SCALE, and current prescribing guidelines.
Read clinical reviewA clinical guide to switching between Ozempic (semaglutide) and liraglutide, covering dose conversion, washout timing, side-effect management, and what trial data show about each drug's efficacy.
Read clinical reviewA clinical comparison of semaglutide (Ozempic) and tirzepatide (Mounjaro) side-effect profiles, drawing on SUSTAIN and SURPASS trial data, discontinuation rates, and GI tolerability.
Read clinical reviewA detailed comparison of Ozempic (semaglutide) and Mounjaro (tirzepatide) covering clinical efficacy, cost, insurance coverage, and switching protocols for patients and prescribers.
Read clinical reviewA clinical comparison of semaglutide (Ozempic) and tirzepatide (Mounjaro) for glycemic control and weight loss, with trial data from SUSTAIN and SURPASS programs.
Read clinical reviewA clinical comparison of Ozempic (semaglutide) and Mounjaro (tirzepatide), including trial data from SUSTAIN and SURPASS programs, and practical guidance on switching between the two GLP-1 medications.
Read clinical reviewA clinical comparison of Ozempic (semaglutide) and retatrutide side-effect profiles, drawing on SUSTAIN and Phase 2 trial data to help patients and prescribers weigh tolerability differences.
Read clinical reviewA clinical comparison of Ozempic (injectable semaglutide) and Rybelsus (oral semaglutide) side-effect profiles, drawing on SUSTAIN and PIONEER trial data to help patients and prescribers choose between formulations.
Read clinical reviewA clinical comparison of injectable semaglutide (Ozempic) and oral semaglutide (Rybelsus) covering A1C reduction, weight loss, trial data from SUSTAIN and PIONEER programs, and guidance on choosing between them.
Read clinical reviewA clinical comparison of Ozempic (injectable semaglutide) and Rybelsus (oral semaglutide), including how to switch between them, dosing equivalence, efficacy data from SUSTAIN and PIONEER trials, and what patients should expect during the transition.
Read clinical reviewCompare the side-effect profiles of Ozempic (semaglutide) and Saxenda (liraglutide 3 mg) across GI symptoms, pancreatitis risk, gallbladder events, and cardiovascular safety using clinical trial data.
Read clinical reviewA clinical comparison of Ozempic (semaglutide) and Saxenda (liraglutide) covering efficacy, cost, insurance coverage, and access for weight management and type 2 diabetes.
Read clinical reviewA clinical comparison of Ozempic (semaglutide) and Saxenda (liraglutide 3 mg), including trial data, dosing differences, and how to switch between them under medical supervision.
Read clinical reviewA clinical comparison of side-effect profiles between Ozempic (semaglutide) and Trulicity (dulaglutide), including GI tolerability, weight effects, cardiovascular outcomes, and switching protocols.
Read clinical reviewA clinical and financial comparison of semaglutide (Ozempic) and dulaglutide (Trulicity) covering efficacy data, insurance coverage, out-of-pocket costs, and switching protocols.
Read clinical reviewA clinical comparison of semaglutide (Ozempic) and dulaglutide (Trulicity) covering HbA1c reduction, weight loss, cardiovascular outcomes, dosing, side effects, and switching protocols.
Read clinical reviewA detailed comparison of Rybelsus (oral semaglutide) and liraglutide covering cost, insurance coverage, clinical efficacy, and practical access considerations for patients and prescribers.
Read clinical reviewA clinical comparison of Rybelsus (oral semaglutide) and liraglutide for A1C reduction, weight loss, and cardiovascular outcomes, with trial data from PIONEER-4, SCALE, and LEADER.
Read clinical reviewA clinical comparison of oral semaglutide (Rybelsus) and injectable liraglutide side effects, including GI tolerability, hypoglycemia risk, and long-term safety data from PIONEER-4 and SCALE trials.
Read clinical reviewClinical comparison of oral semaglutide (Rybelsus) and liraglutide, including efficacy data from PIONEER-4 and SCALE, dose conversion, and how to switch between them without losing glycemic control.
Read clinical reviewA clinical comparison of Rybelsus (oral semaglutide) and retatrutide covering efficacy, cost, insurance access, and practical switching guidance for patients and prescribers.
Read clinical reviewCompare Rybelsus (oral semaglutide) and retatrutide for weight loss and A1C reduction. Cross-trial efficacy data, dosing, mechanisms, and clinical evidence reviewed.
Read clinical reviewA clinical comparison of Rybelsus (oral semaglutide) and retatrutide side effects, drawing from PIONEER and phase 2 trial data to help patients and prescribers weigh tolerability.
Read clinical reviewA clinical comparison of oral semaglutide (Rybelsus) and retatrutide, including weight-loss efficacy, mechanism differences, and how to switch safely between these GLP-1 receptor agonists.
Read clinical reviewA clinical comparison of Rybelsus (oral semaglutide) and Trulicity (dulaglutide) side effects, covering GI tolerability, cardiovascular outcomes, and practical switching guidance from PIONEER and REWIND trial data.
Read clinical reviewA detailed comparison of Rybelsus (oral semaglutide) and Trulicity (dulaglutide) covering cost, insurance coverage, formulary access, clinical efficacy, and switching considerations for patients with type 2 diabetes.
Read clinical reviewA clinical comparison of oral semaglutide (Rybelsus) and dulaglutide (Trulicity) covering A1C reduction, weight loss, cardiovascular outcomes, dosing, and side effects.
Read clinical reviewEvidence-based comparison of Rybelsus (oral semaglutide) and Trulicity (dulaglutide) for type 2 diabetes, including when and how to switch between them safely.
Read clinical reviewSaxenda (liraglutide 3 mg) and generic liraglutide share the same active molecule but differ in dose and approved indication. This clinical comparison breaks down how their side-effect profiles diverge in frequency, severity, and management.
Read clinical reviewA clinical comparison of Saxenda (liraglutide 3 mg) and retatrutide covering efficacy data, pricing, insurance coverage, and access timelines for obesity treatment.
Read clinical reviewHow does Saxenda (liraglutide 3 mg) compare to retatrutide for weight loss? We break down trial data from SCALE and the Phase 2 retatrutide study, covering efficacy, mechanisms, and what the numbers actually mean.
Read clinical reviewCompare Saxenda (liraglutide 3 mg) and retatrutide for weight loss. Learn key trial differences, how to switch between them, and what clinicians recommend for the transition.
Read clinical reviewCompare the side-effect profiles of Saxenda (liraglutide 3 mg) and Rybelsus (oral semaglutide 14 mg) across GI tolerance, injection-site reactions, cardiovascular safety, and discontinuation rates from SCALE and PIONEER trial data.
Read clinical reviewA detailed cost and access comparison of Saxenda (liraglutide 3 mg) and Rybelsus (oral semaglutide), including insurance coverage, out-of-pocket pricing, manufacturer savings programs, and switching considerations.
Read clinical reviewA clinical comparison of Saxenda (liraglutide 3 mg) and Rybelsus (oral semaglutide 14 mg) for weight loss and glycemic control, with trial data from SCALE and PIONEER programs.
Read clinical reviewClinical comparison of Saxenda (liraglutide 3 mg) and Rybelsus (oral semaglutide 14 mg) with evidence-based guidance on switching protocols, efficacy differences, side effects, and cost.
Read clinical reviewShowing the first 60 matches. Use search or filters to narrow the library.